Arrakis raises $38M for new frontier in drug discovery
Boston-based Arrakis has officially launched with a $38 million Series A and a unique mission to bind RNA with small molecules.
Boston-based Arrakis has officially launched with a $38 million Series A and a unique mission to bind RNA with small molecules.